investor information
results, reports and presentations
our fy 2024 and q1 2025 investor presentation was published on 27 may 2025
news and press releases
view the latest news updates from the business
investor information
debt profile
senior secured bonds | issued amount £330m at 8.5% coupon | maturity 15 june 2030
super senior rcf | issued amount £55m | maturity 30 january 2030
credit rating
moodys | rating b2 | outlook stable
s&p | rating b | outlook stable
financial calender
check the dates of our upcoming financial results announcements below
- 27 may 2025
- fy2024 and q1 25 report + presentation
- sept 2025 (tbc)
- q2 2025 report + presentation
- dec 2025 (tbc)
- q3 2025 report + presentation
still have questions?
get in touch
email our team at the details below to get your questions answered or receive more information
still have questions?
get in touch
email our team at the details below to get your questions answered or receive more information
investor@wagamama.com
contact our investor relations team
trg@mhpgroup.com
ask to be added to our investor mailing list for key updates
press@wagamama.com
something else? reach out to our team with your questions
Documents and material hosted on this website are for informational purposes only and do not constitute an offer to sell or the solicitation of an offer to buy any security. Neither Waga BondCo Limited (the “Issuer”) nor Wagamama (Holdings) Limited (the “Company” and, together with its consolidated subsidiaries, the “Group”) make any representation or warranty or other assurance, express or implied, that material hosted on this website or the Group information contained therein or the assumptions on which they are based are accurate, complete, adequate, fair, reasonable or up to date and they should not be relied upon as such. Neither the Issuer nor the Company accepts any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this website and any liability is expressly disclaimed